240 related articles for article (PubMed ID: 23588955)
1. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.
Zagouri F; Sergentanis TN; Bartsch R; Berghoff AS; Chrysikos D; de Azambuja E; Dimopoulos MA; Preusser M
Breast Cancer Res Treat; 2013 May; 139(1):13-22. PubMed ID: 23588955
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
Zagouri F; Zoumpourlis P; Le Rhun E; Bartsch R; Zografos E; Apostolidou K; Dimopoulos MA; Preusser M
Cancer Treat Rev; 2020 Aug; 88():102046. PubMed ID: 32599393
[TBL] [Abstract][Full Text] [Related]
3. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
[TBL] [Abstract][Full Text] [Related]
5. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Bonneau C; Paintaud G; Trédan O; Dubot C; Desvignes C; Dieras V; Taillibert S; Tresca P; Turbiez I; Li J; Passot C; Mefti F; Mouret-Fourme E; Le Rhun E; Gutierrez M
Eur J Cancer; 2018 May; 95():75-84. PubMed ID: 29635147
[TBL] [Abstract][Full Text] [Related]
6. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
8. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
Oberkampf F; Gutierrez M; Trabelsi Grati O; Le Rhun É; Trédan O; Turbiez I; Kadi A; Dubot C; Taillibert S; Vacher S; Bonneau C
Neuro Oncol; 2023 Feb; 25(2):365-374. PubMed ID: 35868630
[TBL] [Abstract][Full Text] [Related]
11. The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: A systematic review and pooled analysis.
Lee YC; Hsieh CC; Chuang JP; Li CY
Curr Probl Cancer; 2017; 41(5):355-370. PubMed ID: 28779849
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ
Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282
[TBL] [Abstract][Full Text] [Related]
13. [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
Cochereau D; Da Costa S; Le Maignan C; Gauthier H; Cochereau J; Espié M; Giacchetti S; Teixeira L
Bull Cancer; 2016 May; 103(5):444-54. PubMed ID: 26987841
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
18. [Trastuzumab in early breast cancer].
Ismaili N; Elmajjaoui S; Tahri A; Benjaafar N; Errihani H; Belbaraka R
Presse Med; 2013; 42(7-8):1069-80. PubMed ID: 23578469
[TBL] [Abstract][Full Text] [Related]
19. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.
Perissinotti AJ; Reeves DJ
Ann Pharmacother; 2010 Oct; 44(10):1633-40. PubMed ID: 20807868
[TBL] [Abstract][Full Text] [Related]
20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
